

Special Issue

Protein Kinase Inhibitors: Synthesis and Applications

Message from the Guest Editors

The abnormality of protein kinase activity is involved in the pathogenesis of all kinds of diseases including cancer, inflammatory, cardiovascular, nervous and degenerative diseases, and have become one of the most important drug targets in the 21st century. Especially receptor tyrosine kinase signaling pathways have been essential targets in cancer therapy. Up to now, 89 protein kinase inhibitors have been approved and several hundreds have been used in the clinics. However, protein kinases remain to be discovered as targets for new biological processes and disease areas leading to the development and application of novel protein kinase inhibitors.

This Special Issue provides a broad survey to release your most recent work on synthesis and applications, new strategies and technologies on the generation or evaluation of protein kinase inhibitors in different disease areas. Original research articles or reviews aiming at the development and applications of protein kinase inhibitors in different fields are welcome.

Guest Editors

Dr. Cheng Wang


School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China

Dr. Benedict-Tilman Berger

Structural Genomics Consortium, Johann Wolfgang Goethe University,
Buchmann Institute for Molecular Life Sciences, D-60438 Frankfurt am
Main, Germany

Deadline for manuscript submissions

closed (31 October 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/127096

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).